TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Kymera Therapeutics ( (KYMR) ).
On December 8, 2025, Kymera Therapeutics announced positive results from their BroADen Phase 1b clinical trial of KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The trial demonstrated significant STAT6 degradation and reductions in Type 2 inflammatory biomarkers, with KT-621 showing promising clinical activity and safety profile. These results suggest KT-621’s potential as a first-in-class oral treatment for Type 2 inflammatory diseases, with ongoing and planned trials aiming to further its development.
The most recent analyst rating on (KYMR) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.
Spark’s Take on KYMR Stock
According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.
Kymera Therapeutics’ overall stock score is primarily impacted by its financial challenges, with declining revenues and negative cash flows being significant concerns. The technical analysis provides a positive outlook with bullish momentum, but valuation remains unattractive due to ongoing losses. The earnings call highlights strategic advancements and a strong cash position, but high expenses and trial challenges temper optimism.
To see Spark’s full report on KYMR stock, click here.
More about Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of oral small molecule degrader medicines for immunological diseases.
Average Trading Volume: 754,326
Technical Sentiment Signal: Buy
Current Market Cap: $4.79B
See more data about KYMR stock on TipRanks’ Stock Analysis page.